Thus, the search of new druggable cavities different from the catalytic site together with the discovery of new molecules able to bind this kinase with allosteric modulation will be an interesting approach for the development of more effective treatments not only for cancer, including SCLC, but also for ALS and other related TDP-43 proteinopathies. Here, TARDBP is linked to cancer.